PONTE VEDRA, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that Guy Guglielmino joined the Company as Chief Commercial Officer. In this new position, Mr. Guglielmino will lead Treace's commercial efforts and play a pivotal role in driving the Company's next phase of rapid innovation, strategic product commercialization, and growth. "I am thrilled to welcome Guy to the Treace team," said John T. Treace, CEO, Founder and B

PONTE VEDRA, Fla., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced Nathan Minnich has been appointed Sr. Vice President, Marketing, effective immediately. In this new position, Mr. Minnich will lead all aspects of Treace's marketing efforts, with a focus on expanding the Company's physician outreach, patient awareness and market penetration efforts.  "I am delighted to welcome Nathan to the Treace team," said John T. Treace, CEO, Fou

PONTE VEDRA, Fla., July 12, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that Julie Dewey will join the Company as Chief Communications and Investor Relations Officer, effective July 17, 2023. In this new position, Ms. Dewey will lead all aspects of Treace's corporate communications and investor relations engagement, with a focus on expanding the company's outreach with the investment community and broadening the Company's relationships wit

PONTE VEDRA, Fla., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced the appointment of Lance E. Berry and Jane E. Kiernan to its board of directors, effective October 1, 2022. "With decades of combined experience leading medical device companies, Lance and Jane strengthen the expertise of our Company's board of directors," said James T. Treace, the Company's Chairman of the Board. "Our executive leadership and board look forward to their support and guidance through our next phase of grow

MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders.  "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics.  "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo

PONTE VEDRA, Fla., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced the appointment of Betsy Hanna and Deepti Jain to its Board of Directors effective October 1, 2021. "With decades of combined experience in healthcare leadership, Ms. Hanna and Ms. Jain strengthen the expertise of our Company's Board of Directors," said James T. Treace, the Company's Chairman of the Board. "Our executive leadership and board are pleased to add two individuals with their stellar reputa

PONTE VEDRA, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced its preliminary, unaudited fourth quarter and full-year 2024 results. Highlights: Preliminary revenue of $68.4 million to $68.8 million in the fourth quarter of 2024, an approximate 10% increase at the midpoint over the same period in 2023.Preliminary revenue of $209.0 million to $209.4 million for the full-year 2024, an approximate 12% increase at the midpoint

PONTE VEDRA, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, beginning at approximately 9:00 am PT. A live webcast and replay of the fireside chat will be available on the Company's investors relations website at https://investors.treace.com/. Internet Posting of Information Treace

PONTE VEDRA, Fla., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the limited market release and first surgical cases utilizing the Percuplasty™ Percutaneous 3D Bunion Correction® System and Procedure. The Percuplasty™ System provides an instrumented, reproducible approach to 3D correction of the bunion deformity through cosmetically appealing, percutaneous incisions designed to minimize post-op pain and swelling, and help pati

PONTE VEDRA, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the successful completion of the first cases utilizing SpeedPlate™ MicroQuad™ implants. The MicroQuad™ implant expands upon the broad utility of the SpeedPlate™ platform, which is designed for fast titanium compression fixation. The MicroQuad™ implant has a unique anatomic design with multiple points of fixation on each side of the joint to deliver dynamic compre

PONTE VEDRA, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the successful completion of the first cases combining IntelliGuide™ PSI technology with the Adductoplasty® System for a CT-based, patient specific correction personalized to the patient's unique midfoot deformity. IntelliGuide™ PSI, incorporating RedPoint™ technology, is the first and only patient-specific cut guide system available for correction of bunion and/

PONTE VEDRA, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that Guy Guglielmino joined the Company as Chief Commercial Officer. In this new position, Mr. Guglielmino will lead Treace's commercial efforts and play a pivotal role in driving the Company's next phase of rapid innovation, strategic product commercialization, and growth. "I am thrilled to welcome Guy to the Treace team," said John T. Treace, CEO, Founder and B

PONTE VEDRA, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, beginning at approximately 8:00 am ET. A live webcast and replay of the fireside chat will be available on the Company's investors relations website at https://inve

PONTE VEDRA, Fla., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Revenue of $45.1 million in third quarter 2024 increased 11% over same period in 2023Third quarter 2024 net loss was ($15.4) million compared to ($17.5) million for same period in 2023. Adjusted EBITDA loss improved 45% to ($5.1) million in the third quarter 2024 compared to ($9.2

PONTE VEDRA, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024, beginning at approximately 11:45 am ET. A live webcast and replay of the fireside chat will be available on the Company's investors relations website at https://investor

PONTE VEDRA, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today commented on the recently released Centers for Medicare & Medicaid Services (CMS) Calendar Year 2025 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Final Rule, effective January 1, 2025. The Final Rule and accompanying Addenda include the reassignment of Current Procedural Terminology (CPT) code 28297 (a primary code used for Lap

Lake Street initiated coverage of Treace Medical Concepts with a rating of Buy and set a new price target of $14.50

Analyst resumed coverage of Treace Medical Concepts with a rating of Neutral and set a new price target of $8.00

UBS downgraded Treace Medical Concepts from Buy to Neutral and set a new price target of $6.50 from $16.00 previously

Morgan Stanley downgraded Treace Medical Concepts from Overweight to Equal-Weight and set a new price target of $5.50 from $15.00 previously

Truist downgraded Treace Medical Concepts from Buy to Hold and set a new price target of $7.00 from $17.00 previously

Stifel downgraded Treace Medical Concepts from Buy to Hold and set a new price target of $6.00 from $15.00 previously

JP Morgan downgraded Treace Medical Concepts from Overweight to Neutral and set a new price target of $8.00 from $15.00 previously

BTIG Research downgraded Treace Medical Concepts from Buy to Neutral

UBS initiated coverage of Treace Medical Concepts with a rating of Buy and set a new price target of $24.00

Truist initiated coverage of Treace Medical Concepts with a rating of Buy and set a new price target of $33.00

4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

PONTE VEDRA, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced its preliminary, unaudited fourth quarter and full-year 2024 results. Highlights: Preliminary revenue of $68.4 million to $68.8 million in the fourth quarter of 2024, an approximate 10% increase at the midpoint over the same period in 2023.Preliminary revenue of $209.0 million to $209.4 million for the full-year 2024, an approximate 12% increase at the midpoint

PONTE VEDRA, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the third quarter of 2024 after the close of trading on Tuesday, November 5, 2024. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in nu

PONTE VEDRA, Fla., July 18, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the second quarter of 2024 after the close of trading on Tuesday, August 6, 2024. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbe

PONTE VEDRA, Fla., April 09, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the first quarter of 2024 after the close of trading on Tuesday, May 7, 2024. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in number

PONTE VEDRA, Fla., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the fourth quarter and full year of 2023 after the close of trading on Tuesday, February 27, 2024. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will rece

PONTE VEDRA, Fla., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced its preliminary, unaudited fourth quarter and full-year 2023 revenue results. Highlights: Preliminary revenue of $61.8 million to $62.2 million in the fourth quarter of 2023, an approximate 25% increase at the midpoint over the same period in 2022. Preliminary revenue of $186.7 million to $187.1 million for the full-year 2023, an approximate increas

PONTE VEDRA, Fla., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction® Procedure, today announced that it will release financial results for the third quarter of 2023 after the close of trading on Thursday, November 9, 2023. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin

PONTE VEDRA, Fla., July 18, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced that it will release financial results for the second quarter of 2023 after the close of trading on Tuesday, August 8, 2023. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and archived we

PONTE VEDRA, Fla., April 20, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that it will release financial results for the first quarter of 2023 after the close of trading on Monday, May 8, 2023. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to joi

PONTE VEDRA, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that it will release financial results for the fourth quarter and full year of 2022 after the close of trading on Tuesday, March 7, 2023. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a